A Novel Neuromodulation Approach to Target Small Fiber Neuropathy Early in Diabetes and Measure Functional Recovery

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Over 18 years old

• Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic

• Diagnosis of medically refractory pain secondary to diabetic neuropathy

• Presence of pain for 12 months

• Lower limb pain intensity score ≥4 on a visual analog scale

• DN4 ≥4

• Pass pre-operative neuropsychological assessment (surgical group only)

• Capable of providing informed consent

Locations
United States
Ohio
The Ohio State University Wexner Medical Center
RECRUITING
Columbus
Contact Information
Primary
Alexander Price
Alexander.Price2@osumc.edu
614-366-7822
Backup
Uchechi Okafor
Uchechi.Okafor@osumc.edu
614.293.4876
Time Frame
Start Date: 2024-04-17
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 60
Treatments
No_intervention: Conventional Medical Management (CMM). Group1
Active_comparator: Spinal Cord Stimulator (SCS) immediate activation. Group 2
Active_comparator: Spinal Cord Stimulator (SCS) Delayed activation. Group 3
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Neuright, Inc.
Leads: Ohio State University

This content was sourced from clinicaltrials.gov